9,096 Shares in PetMed Express, Inc. (NASDAQ:PETS) Purchased by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC acquired a new position in shares of PetMed Express, Inc. (NASDAQ:PETSGet Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 9,096 shares of the company’s stock, valued at approximately $292,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Dark Forest Capital Management LP acquired a new position in PetMed Express during the third quarter worth about $33,000. Geneos Wealth Management Inc. raised its position in PetMed Express by 45.4% during the third quarter. Geneos Wealth Management Inc. now owns 3,514 shares of the company’s stock worth $93,000 after acquiring an additional 1,098 shares during the last quarter. FMR LLC raised its position in PetMed Express by 9,448.1% during the first quarter. FMR LLC now owns 5,156 shares of the company’s stock worth $118,000 after acquiring an additional 5,102 shares during the last quarter. Fifth Third Bancorp raised its position in PetMed Express by 5.3% during the fourth quarter. Fifth Third Bancorp now owns 8,071 shares of the company’s stock worth $204,000 after acquiring an additional 405 shares during the last quarter. Finally, Maryland State Retirement & Pension System acquired a new position in PetMed Express during the third quarter worth about $219,000. 80.50% of the stock is currently owned by hedge funds and other institutional investors.

PETS stock traded up $0.63 on Tuesday, hitting $25.41. 3,896 shares of the company were exchanged, compared to its average volume of 406,662. PetMed Express, Inc. has a twelve month low of $21.64 and a twelve month high of $46.67. The business’s fifty day moving average is $26.29 and its two-hundred day moving average is $26.65. The stock has a market capitalization of $533.08 million, a price-to-earnings ratio of 22.94 and a beta of 0.45.

PetMed Express (NASDAQ:PETSGet Rating) last issued its quarterly earnings results on Monday, January 24th. The company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.30 by ($0.09). PetMed Express had a return on equity of 16.00% and a net margin of 7.83%. The company had revenue of $60.72 million for the quarter, compared to analyst estimates of $61.90 million. During the same period last year, the company posted $0.38 EPS. Sell-side analysts predict that PetMed Express, Inc. will post 1.06 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, February 18th. Investors of record on Monday, February 7th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 4.72%. The ex-dividend date was Friday, February 4th. PetMed Express’s dividend payout ratio (DPR) is 111.11%.

A number of research firms have recently weighed in on PETS. StockNews.com began coverage on shares of PetMed Express in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Sidoti raised shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $32.00 price objective for the company in a research report on Thursday, January 20th. Morgan Stanley cut their price objective on shares of PetMed Express from $25.00 to $21.00 and set an “underweight” rating for the company in a research report on Tuesday, January 25th. Finally, Zacks Investment Research raised shares of PetMed Express from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $27.00.

PetMed Express Company Profile (Get Rating)

PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Further Reading

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetMed Express, Inc. (NASDAQ:PETSGet Rating).

Institutional Ownership by Quarter for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.